Viridian Therapeutics IncDE
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
VRDN$30.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year EndedDecember 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue: | |||
| Collaboration revenue - related party | $314 | $1,772 | $2,963 |
| Operating expenses: | |||
| Research and development (including related party expenses of $12,035, $5,619, and $— during the years ended December 31, 2023, 2022, and 2021 respectively) | 159,765 | 100,894 | 56,886 |
| General and administrative | 94,999 | 35,182 | 25,805 |
| Total operating expenses | 254,764 | 136,076 | 82,691 |
| Loss from operations | (254,450) | (134,304) | (79,728) |
| Other income (expense): | |||
| Interest and other income | 18,563 | 4,916 | 318 |
| Interest and other expense | (1,847) | (486) | (3) |
| Other income, net | 16,716 | 4,430 | 315 |
| Net loss | $(237,734) | $(129,874) | $(79,413) |
| Net loss per share, basic and diluted | $(5.31) | $(4.05) | $(6.66) |
| Weighted-average shares used to compute basic and diluted net loss per share | 44,755,475 | 32,087,293 | 11,918,712 |
| Comprehensive loss: | |||
| Net loss | $(237,734) | $(129,874) | $(79,413) |
| Other comprehensive (loss) income: | |||
| Change in unrealized (loss) gain on investments | 728 | (233) | (149) |
| Total other comprehensive (loss) gain | 728 | (233) | (149) |
| Total comprehensive loss | $(237,006) | $(130,107) | $(79,562) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.